Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5PG6C)

Drug Name
BMS-182874 Drug Info
Synonyms
BMS-182874; Bms 182874; 5-Ddins; 153042-42-3; CHEMBL267458; 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-1-naphthalenesulfonamide; 1-Naphthalenesulfonamide, 5-(dimethylamino)-N-(3,4-dimethyl-5-isoxazolyl)-; Tocris-1441; AC1L3UAG; SCHEMBL802730; ZINC5803; CHEBI:92993; DTXSID60165205; BDBM50034435; NCGC00025164-01; LS-173440; L009159; BRD-K56509348-003-01-3; 5-Dimethylamino-naphthalene-1-sulfonic acid (3,4-dimethyl-isoxazol-5-yl)-amide; 5-Dimethylamino-naphthalene-1-sulfonic acid (3,4-dimethyl-2,3-dihydro-oxazol-5-yl)-amide
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Terminated [1]
Cross-matching ID
PubChem CID
122272
ChEBI ID
CHEBI:92993
CAS Number
CAS 153042-42-3
TTD Drug ID
DM5PG6C

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Endothelin A receptor (EDNRA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [3]
Ambrisentan DMD1QXW Pulmonary arterial hypertension BB01.0 Approved [4]
Macitentan DMP79A1 Cardiovascular disease BA00-BE2Z Approved [5]
Sparsentan DMMP51W IgA nephropathy MF8Y Approved [6]
LU302146 DMMJVXZ Pulmonary hypertension BB01 Approved [7]
Atrasentan DMM74PK Diabetic nephropathy GB61.Z Phase 3 [8]
Clazosentan DMQSBX4 Cerebral vasospasm BA85.Z Phase 3 [9]
PF-1228305 DMS1EQ7 Pulmonary hypertension BB01 Phase 3 [10]
Darusentan DMN8DQH Hypotension BA20-BA21 Phase 3 [11]
BQ-123 DM0MO8I Pulmonary arterial hypertension BB01.0 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endothelin A receptor (EDNRA) TTKRD0G EDNRA_HUMAN Inhibitor [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004811)
2 Biphenylsulfonamide endothelin receptor antagonists. 2. Discovery of 4'-oxazolyl biphenylsulfonamides as a new class of potent, highly selective ET... J Med Chem. 2000 Aug 10;43(16):3111-7.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
7 Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
8 Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
9 Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
10 Pfizer. Product Development Pipeline. March 31 2009.
11 Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
12 Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.